THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.19] ID: TIP-MED-000251

Teriparatide (Recombinant PTH 1-34 Osteoanabolic Injection)

Active Ingredient / Scientific Identity: Teriparatide • Class: Recombinant Human Parathyroid Hormone Fragment [rhPTH(1-34)] (Osteoanabolic Bone-Forming Agent)

⚖️ Compare Profile
Generic / Entity NameTeriparatide (Recombinant PTH 1-34 Osteoanabolic Injection) ([12.19])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassRecombinant Human Parathyroid Hormone Fragment [rhPTH(1-34)] (Osteoanabolic Bone-Forming A
Available Dosage FormsPre-filled Multi-Dose Pen Injector / Cartridge: 20 mcg per 80 microlitre dose (600 mcg/2.4 mL or 750 mcg/3 mL
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Mild-to-moderate CKD: No adjustment. Severe CKD: Caution (prolonged PTH half-life and secondary hyperparathyroidism).
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Teriparatide (Recombinant PTH 1-34 Osteoanabolic Injection) (TIP-MED-000251, Reference Code [12.19]) is classified under Osteoporosis & Bone Metabolism Medicines (Ch 12) as a Recombinant Human Parathyroid Hormone Fragment [rhPTH(1-34)] (Osteoanabolic Bone-Forming Agent). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.19], p. 164): Bonmax-PTH, Forteo, Gemtide, Osteoters — Strengths & Dosage Forms: Pre-filled Multi-Dose Pen Injector / Cartridge: 20 mcg per 80 microlitre dose (600 mcg/2.4 mL or 750 mcg/3 mL pen = 28 doses).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.19], p. 164): Bonmax-PTH, Forteo, Gemtide, Osteoters — Strengths & Dosage Forms: Pre-filled Multi-Dose Pen Injector / Cartridge: 20 mcg per 80 microlitre dose (600 mcg/2.4 mL or 750 mcg/3 mL pen = 28 doses).
Dosage Forms & Available Strengths:
Pre-filled Multi-Dose Pen Injector / Cartridge: 20 mcg per 80 microlitre dose (600 mcg/2.4 mL or 750 mcg/3 mL pen = 28 doses).
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Intermittent once-daily pulsatile administration of the biologically active N-terminal 34-amino-acid fragment of PTH preferentially stimulates osteoblast maturation and new trabecular/cortical bone formation over osteoclast resorption.

4. Therapeutic Indications & Evidence-Supported Uses

  • Severe postmenopausal, male, or glucocorticoid-induced osteoporosis at very high risk of vertebral/non-vertebral fracture or after bisphosphonate failure

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: 20 mcg SC once daily into the thigh or abdomen (maximum cumulative lifetime duration: 24 months). • Paediatric: CONTRAINDICATED in children and young adults with open epiphyses (osteosarcoma risk).

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Mild-to-moderate CKD: No adjustment. Severe CKD: Caution (prolonged PTH half-life and secondary hyperparathyroidism). • Hepatic: No routine adjustment.
Elimination & Renal Adjustment:
Renal: Mild-to-moderate CKD: No adjustment. Severe CKD: Caution (prolonged PTH half-life and secondary hyperparathyroidism). • Hepatic: No routine adjustment.
Hepatic Impairment Considerations:
Renal: Mild-to-moderate CKD: No adjustment. Severe CKD: Caution (prolonged PTH half-life and secondary hyperparathyroidism). • Hepatic: No routine adjustment.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Pre-existing hypercalcaemia, primary/tertiary hyperparathyroidism, Paget's disease of bone, unexplained elevated alkaline phosphatase, prior external beam or implant skeletal radiation therapy, bone metastases or skeletal malignancies, open epiphyses. • Precautions: Cold-chain biologic (store at 2-8°C; never freeze); first few doses may cause transient orthostatic dizziness/palpitations within 4 hours; after completing the 24-month osteoanabolic course, patients MUST transition immediately to an antiresorptive (Alendronate, Zoledronic acid, or Denosumab) or newly formed bone density will rapidly be lost.

Key Clinical Precautions: Renal: Mild-to-moderate CKD: No adjustment. Severe CKD: Caution (prolonged PTH half-life and secondary hyperparathyroidism). • Hepatic: No routine adjustment.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Mild transient hypercalcaemia (4-6 hours post-dose), orthostatic dizziness, leg cramps, nausea, injection-site erythema.
  • Symptomatic hypercalcaemia, urolithiasis, theoretical osteosarcoma risk in high-risk bone pathology.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Digoxin -> transient post-dose hypercalcaemia produced by Teriparatide may predispose to acute digoxin toxicity; Loop diuretics (Furosemide) / Thiazides -> alter renal calcium handling

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Keep pen refrigerated at 2-8°C at all times (remove, inject 20 mcg into thigh/abdomen, and return to fridge immediately—do not keep at room temperature like insulin!); sit or lie down for the first few doses in case of dizziness; discard pen after 28 days of use.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM | Compendia: IP 2026 / NFI 7th Ed 2026 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.19] (p. 164)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.